Previous Summit

align="left">Much emphasis has been placed on helping Europe climb back to the top of the R&D ladder. The European pharmaceutical sector must currently focus on innovative solutions which can integrate seamlessly with existing technologies and strategies, which are key factors in bringing drugs to market quicker and more effectively. Given the multitude of new pharmaceuctical R&D institutes and the determination of the EU to revive Europe's status as an innovation leader in drug discovery, returns on such R&D investment over the next few years could potentially boom. Leaders in the R&D space know that now is the time to commit to drug discovery.

"For those interested in emerging drug discovery technologies and concepts, there are few conferences that meet the standards of the NGP series. The conference is professionally organized with a focus on shaping agendas for the individual needs of the"

Ted Torphy, VP Head of External Innovation, Johnson & Johnson